Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia | Nature

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript. Advertisement Nature volume  478,  pages 529–533 (2011)Cite this article 25k Accesses 1229 Citations 50 Altmetric Metrics details This article has been updated Recurrent chromosomal translocations involving the mixed lineage leukaemia (MLL) gene initiate aggressive forms of leukaemia, which are often refractory to conventional therapies1. Many MLL-fusion partners are members of the super elongation complex (SEC), a critical regulator of transcriptional elongation, suggesting that aberrant control of this process has an important role in leukaemia induction2,3. Here we use a global proteomic strategy to demonstrate that ML

saved by

• Gem Wu